REGULATED PRESS RELEASE published on 06/19/2024 at 17:45, 3 months ago Disclosure of trading in own shares from June 10th, 2024, to June 14th, 2024 Lagardère SA disclosed trading in own shares from June 10th, 2024, to June 14th, 2024, as per the mandate with an investment services provider Lagardère SA Trading Disclosure Investment Own Shares
REGULATED PRESS RELEASE published on 06/19/2024 at 17:45, 3 months ago Déclaration des transactions sur actions propres réalisées du 10 juin 2024 au 14 juin 2024. Présentation détaillée transaction par transaction
REGULATED PRESS RELEASE published on 06/19/2024 at 17:45, 3 months ago Disclosure of trading in own shares from June 10th, 2024, to June 14th, 2024. Detailed information per transaction
BRIEF published on 06/11/2024 at 17:50, 3 months 8 days ago Lagardère SA : Déclaration des transactions sur actions propres réalisées du 3 au 7 juin 2024 Actions Propres Transactions Investissements LAGARDERE
BRIEF published on 06/11/2024 at 17:50, 3 months 8 days ago Lagardère SA Discloses Own Share Trading Activities from June 3 to June 7, 2024 Investment Financial Disclosure LAGARDERE Share Trading June 2024
REGULATED PRESS RELEASE published on 06/11/2024 at 17:45, 3 months 8 days ago Disclosure of trading in own shares from Jun 3rd, 2024, to Jun 7th, 2024 Lagardère SA declares trading in own shares from Jun 3rd to Jun 7th, 2024, as mandated with an investment services provider Lagardère SA Trading Own Shares Regulation Investment Services Provider
REGULATED PRESS RELEASE published on 06/11/2024 at 17:45, 3 months 8 days ago Déclaration des transactions sur actions propres réalisées du 3 juin 2024 au 7 juin 2024 Déclaration des transactions sur actions propres réalisées par Lagardère SA du 3 juin 2024 au 7 juin 2024 conformément à la réglementation en vigueur Actions Propres Déclaration Transactions Lagardère SA Réglementation
REGULATED PRESS RELEASE published on 06/11/2024 at 17:45, 3 months 8 days ago Déclaration des transactions sur actions propres réalisées du 3 juin 2024 au 7 juin 2024. Présentation détaillée transaction par transaction
REGULATED PRESS RELEASE published on 06/11/2024 at 17:45, 3 months 8 days ago Disclosure of trading in own shares from Jun 3rd, 2024, to Jun 7th, 2024. Detailed information per transaction
BRIEF published on 06/07/2024 at 17:50, 3 months 12 days ago Lagardère SA finalise avec succès son opération de refinancement Dette Refinancement Crédit LAGARDERE Vivendi
Published on 09/20/2024 at 15:00, 1 hour 23 minutes ago DISCOVER FH Collaboration With Family Heart Foundation, UT Southwestern, and Partners
Published on 09/20/2024 at 15:00, 1 hour 23 minutes ago Tacora Resources Inc. completes CCAA Sale Transaction, Emerging with a Strengthened Balance Sheet, Renewed Conviction on High-Grade Iron Ore, and a Plan to Realize Production Growth
Published on 09/20/2024 at 14:30, 1 hour 53 minutes ago Focus Universal Inc. Announces Listing Transfer to Nasdaq Capital Market
Published on 09/20/2024 at 14:00, 2 hours 23 minutes ago Scepter Files Form 10 with SEC Paving the Way for Strategic Growth
Published on 09/20/2024 at 14:00, 2 hours 23 minutes ago Tectonic Metals Announces Results Of 2024 Annual General Meeting
Published on 09/20/2024 at 15:29, 53 minutes ago Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU)
Published on 09/20/2024 at 15:14, 1 hour 9 minutes ago a sknet becomes part of Academic Software Resulting in a powerful combination of two leaders in digital education.
Published on 09/20/2024 at 14:59, 1 hour 24 minutes ago Form 8.3 - The Vanguard Group, Inc.: Darktrace plc
Published on 09/20/2024 at 14:58, 1 hour 25 minutes ago Form 8.3 - The Vanguard Group, Inc.: International Distribution Services plc
Published on 09/20/2024 at 14:57, 1 hour 26 minutes ago Form 8.3 - The Vanguard Group, Inc.: SEGRO plc
Published on 09/20/2024 at 08:45, 7 hours 38 minutes ago BAIKOWSKI : Rapport financier semestriel 2024
Published on 09/20/2024 at 08:00, 8 hours 23 minutes ago MEDESIS PHARMA : Résultats encourageants de la première phase de l’essai clinique de phase 2a pour le traitement de la maladie d’Alzheimer avec le NanoLIthium